Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Tabelecleucel

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA declines to approve Atara Biotherapeutics' cancer therapy
    FDA declines to approve Atara Biotherapeutics' cancer therapy

    17 Jan 2025

    // PRESS RELEASE

    https://investors.atarabio.com/news-events/press-releases/detail/367/atara-biotherapeutics-provides-regulatory-and-business

    PRESS RELEASE
    17 Jan 2025
    Share Share
    FDA Grants Priority Review For Pierre Fabre's Tabelecleucel BLA
    FDA Grants Priority Review For Pierre Fabre's Tabelecleucel BLA

    18 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-inc-announces-the-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-cel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferat-302200702.html

    PR NEWSWIRE
    18 Jul 2024
    Share Share
    FDA Accepts Atara's BLA For Tab-cel With Priority Review
    FDA Accepts Atara's BLA For Tab-cel With Priority Review

    17 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240717492765/en

    BUSINESSWIRE
    17 Jul 2024
    Share Share
    Atara Biotherapeutics’ Ebvallo™ Wins Prix Galien Award for Orphan/Rare Diseases
    Atara Biotherapeutics’ Ebvallo™ Wins Prix Galien Award for Orphan/Rare Diseases

    21 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240621317043/en

    BUSINESSWIRE
    21 Jun 2024
    Share Share
    Pierre Fabre announces the submission by Atara of Tabelecleucel (Tab-cel®)
    Pierre Fabre announces the submission by Atara of Tabelecleucel (Tab-cel®)

    20 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-laboratories-announces-the-submission-by-atara-biotherapeutics-of-tabelecleucel-tab-cel-biologics-license-application-for-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-with-u-302149982.html

    PR NEWSWIRE
    20 May 2024
    Share Share
    Atara Submits Tab-cel BLA For Transplant Lymphoproliferative Disease
    Atara Submits Tab-cel BLA For Transplant Lymphoproliferative Disease

    20 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240520985176/en

    BUSINESSWIRE
    20 May 2024
    Share Share